Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study
Authors' conclusion
After 12 months of UPA treatment, a substantial proportion of RA patients achieved combined clinical and US remission, independent of prior bDMARDs use or monotherapy.
Study context
- Population
- Rheumatoid arthritis (RA) patients initiating upadacitinib (UPA) at 9 Italian rheumatology centres
- Participants
- 115 patients9 Italian centres
- Outcome
- Proportion of patients achieving combined clinical and US remission
- Follow-up
- Week 48
Methodological detailsmulticentre, real-world, 12-month follow-up
- Multicentre
- Real-world
- 12-month follow-up
Main finding
As reported in the abstract
Combined clinical and US remission (single-group, patients initiating UPA)
Combined clinical and ultrasound (US) remission at week 48
72%
Observational data: associations, not effects.
Secondary outcomes
Combined clinical and US remission (single-group, patients initiating UPA) · week 12
- Combined clinical and US remission at week 12
- 35%
Combined clinical and US remission (single-group, patients initiating UPA) · week 24
- Combined clinical and US remission at week 24
- 55%
Absence of power Doppler (PD) signal · week 24 and week 48
- Absence of PD signal at week 24
- More than 60%
- Absence of PD signal by week 48
- over 80%
Baseline corticosteroid use and remission
- Baseline corticosteroid use linked to lower likelihood of achieving remission
- 65% lower
Predictors of remission
- Younger age, lower baseline CDAI, and higher ESR associated with higher remission rates
Clinical vs US remission concordance
- The majority of patients in clinical remission also achieved US remission
Original publication
Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study. Arthritis Res Ther. Published 3 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →